Oncology Market - By Cancer Diagnostics & Treatment, By Cancer Type, By End-use & Forecast, 2023

Description

List of Tables

Oncology Market is expected to garner commendable gains over 2023 to 2032, fueled by the growing cancer prevalence worldwide. As per WHO statistics, cancer is one of the leading causes of fatalities worldwide, resulting in nearly 10 million deaths in 2020. This calls for broad treatment options to treat the disease. Various therapies such as chemotherapy, surgery, and radiation therapy are employed in cancer therapy subject to the pivotal benefits in terms of providing palliative as well as curative effect in cancer treatment.

Technological innovations by researchers, government officials, and market players in developed economies would further influence the industry growth through 2032. For instance, the Government Office for Technology Transfer (GOTT), UK, funded the National Physical Laboratory's novel development of ultrasound technology to enhance breast cancer diagnosis.

The oncology industry is segmented into cancer diagnostics and treatment, cancer, end-use, and region.

Based on cancer diagnostics and treatment, the cancer diagnostics segment is slated to churn profitable returns over the due course of time. Fundamental factors driving the segmental growth include growing incidences of cancer and technological advancements in the space. In addition, detecting cancer with only physical exams or biomarker tests is noted to be a monotonous task while imaging test is essential for conformation. These trends thus prompt the demand for advanced imaging modalities, stimulating the market growth.

Considering the cancer, oncology market share from breast cancer segment would accrue massive gains over the next ten years, owing to the alarming breast cancer incidences due to rising obesity, hormonal imbalance cases, and age-related risks. As per Cancer.net statistics, it has been projected that breast cancer could lead to more than 43,500 deaths in the United States in 2023. Besides, various government efforts such as BreastScreen Aotearoa in New Zealand and other countries, providing free tests to women would further boost the market size.

Oncology treatment is being largely accommodated in specialty clinics over the recent years. These healthcare settings stand as advanced cancer care establishments that cater to specific types of cancer treatments. Increased availability of advanced technology for detection and screening and specialist oncologists across these settings would further encourage the business growth.

Not to mention, growing availability of advanced technology for screening and diagnosis would offer attractive opportunities to patients for cancer treatment.

Regionally, Asia Pacific is likely to emerge as a regional hotspot for oncology industry. As per reports, the APAC oncology market is predicted to grow at more than 11.5% CAGR between 2023 to 2032. The regional growth can be credited to the burgeoning cases of cancer in countries such as India, Japan, and China. For the record, a cancer registry data reveals that there would be approximately 800,000 new cancer cases in India every year.

Furthermore, growing cognizance among the regional population about the newly developed cancer medications by key pharmaceutical companies in the Asia Pacific would foster the regional market growth in the years ahead.

Product Code: 4879

Chapter 1 Methodology & Scope

1.1 Methodology
1.2 Market scope and definitions
1.3 Base estimates and working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Oncology industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Cancer diagnostic & treatment trends
- 2.1.3 Cancer type trends
- 2.1.4 End-use trends
- 2.1.5 Regional trends

Chapter 3 Oncology Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Rising incidence of cancer globally
  - 3.3.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
  - 3.3.1.3 Growing number of diagnostic laboratories in developing countries
  - 3.3.1.4 Technological advancements in developed countries
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 High capital investment coupled with high cost associated with diagnostic imaging system
  - 3.3.2.2 High risk of side effects associated with cancer treatment and risks associated with CT scanners
  - 3.3.2.3 Dearth of well-skilled and trained oncologists and radiologists
3.4 Growth potential analysis
- 3.4.1 By cancer diagnostics & treatment
- 3.4.2 By cancer type
- 3.4.3 By end-use
3.5 COVID- 19 impact analysis
3.6 Oncology clinical trial volume analysis, 2021
- 3.6.1 Oncology clincial trial volume, by region, 2017 - 2021
- 3.6.2 Oncology clinical trial volume, by cancer type, 2017 - 2021
- 3.6.3 Oncology clinical trial volume, by phase of development, 2017 - 2021
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2021

4.1 Introduction
4.2 Company matrix analysis
4.3 Top oncology drugs, by company, 2021
4.4 Competitive analysis of major market players
- 4.4.1 F. Hoffmann-La Roche
- 4.4.2 Janssen Diagnostics, LCC
- 4.4.3 Pfizer, Inc
- 4.4.4 GE Healthcare
4.5 Oncology drugs company market share analysis, 2021
4.6 Strategic dashboard

Chapter 5 Oncology Market, By Cancer Diagnostics & Treatment

5.1 Key cancer diagnostics & treatment trends
5.2 Cancer diagnostics
- 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.2 Tumor biomarkers tests
  - 5.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.3 Imaging
  - 5.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.4 Biopsy
  - 5.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.5 Liquid biopsy
  - 5.2.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.6 Immunohistochemistry
  - 5.2.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.7 In situ hybridization
  - 5.2.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Cancer treatment
- 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.2 Immunohistochemistry
  - 5.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.3 Targeted therapy
  - 5.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.4 Immunotherapy
  - 5.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.5 Hormonal therapy
  - 5.3.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.6 Others
  - 5.3.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6 Oncology Market, By Cancer Type

6.1 Key cancer type trends
6.2 Lung cancer
- 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Prostate cancer
- 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Colon & rectal cancer
- 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Gastric cancer
- 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Esophageal cancer
- 6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.7 Liver cancer
- 6.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.8 Breast cancer
- 6.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.9 Others
- 6.9.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7 Oncology Market, By End-use

7.1 Key end-use trends
7.2 Hospitals
- 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Diagnostic laboratories
- 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Diagnostic imaging centers
- 7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.5 Academia
- 7.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.6 Specialty clinics
- 7.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.7 Others
- 7.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8 Oncology Market, By Region

8.1 Key regional trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Poland
- 8.3.7 Switzerland
- 8.3.8 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Indonesia
- 8.4.7 Thailand
- 8.4.8 Vietnam
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Columbia
8.6 MEA
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Israel

Chapter 9 Company Profiles

9.1 Abbott
9.2 Bayer AG
9.3 Biocartis
9.4 BioMerieux SA
9.5 Bio-Rad Laboratories
9.6 GE Healthcare
9.7 Astellas Pharma, Inc.
9.8 AstraZeneca
9.9 Janssen Diagnostic LLC (Johnson & Johnson)
9.10 F. Hoffmann-La Roche Ltd
9.11 Sysmex Corporation
9.12 Thermo Fischer Scientific
9.13 Siemens Healthineers
9.14 Kite Pharma (Gilead Sciences Inc)
9.15 Amgen
9.16 AstraZeneca
9.17 Merck & Co.
9.18 Abbive Inc.
9.19 Pfizer